MX2020008106A - Moduladores del receptor nmda espiro-lactama y usos de los mismos. - Google Patents

Moduladores del receptor nmda espiro-lactama y usos de los mismos.

Info

Publication number
MX2020008106A
MX2020008106A MX2020008106A MX2020008106A MX2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A
Authority
MX
Mexico
Prior art keywords
nmda receptor
spiro
receptor modulators
lactam nmda
lactam
Prior art date
Application number
MX2020008106A
Other languages
English (en)
Spanish (es)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of MX2020008106A publication Critical patent/MX2020008106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020008106A 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos. MX2020008106A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US201862718107P 2018-08-13 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2020008106A true MX2020008106A (es) 2020-09-25

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008106A MX2020008106A (es) 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos.

Country Status (15)

Country Link
US (1) US20210047324A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746442A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021512109A (cg-RX-API-DMAC7.html)
KR (1) KR20200115610A (cg-RX-API-DMAC7.html)
CN (1) CN112218866A (cg-RX-API-DMAC7.html)
AU (1) AU2019215049A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015666A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089559A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001990A1 (cg-RX-API-DMAC7.html)
IL (1) IL276330A (cg-RX-API-DMAC7.html)
MX (1) MX2020008106A (cg-RX-API-DMAC7.html)
PE (1) PE20211455A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551140A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007251XA (cg-RX-API-DMAC7.html)
WO (1) WO2019152678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
AU2024354932A1 (en) * 2023-10-03 2026-04-09 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技(上海)有限公司 一种制备二氮杂螺环化合物的方法
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
SG11201505937SA (en) * 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) * 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) * 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) * 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
BR112020015666A2 (pt) 2021-02-23
EP3746442A1 (en) 2020-12-09
PH12020551140A1 (en) 2021-05-31
JP2021512109A (ja) 2021-05-13
CN112218866A (zh) 2021-01-12
JP2024019396A (ja) 2024-02-09
SG11202007251XA (en) 2020-08-28
PE20211455A1 (es) 2021-08-05
WO2019152678A1 (en) 2019-08-08
CL2020001990A1 (es) 2021-03-26
IL276330A (en) 2020-09-30
US20210047324A1 (en) 2021-02-18
KR20200115610A (ko) 2020-10-07
CA3089559A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020550523A1 (en) Modulators of the integrated stress pathway
PH12021552759A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
MY207223A (en) Prodrug modulators of the integrated stress pathway
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
AU2017261336A1 (en) Modulators of the integrated stress pathway
AU2017260367A1 (en) Modulators of the integrated stress pathway
WO2019090085A8 (en) Modulators of the integrated stress pathway
NZ771366A (en) Pyridinyl and pyrazinyl-(aza)indolsulfonamides
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2020012823A (es) Alcoxipiridinil indolsulfonamidas sustituidas.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2025010681A (es) Formulaciones transdermicas
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.